Empaveli Disease Interactions

Pegcetacoplan may predispose patients to serious, life-threatening, or fatal infections caused by encapsulated bacteria including Streptococcus pneumoniae, Neisseria meningitidis types A, C, W, Y, and B, and Haemophilus influenzae type B (Hib). Consider discontinuation of treatment in patients who are undergoing treatment for serious infections. It is recommended to vaccinate all patients against these bacteria according to the most current ACIP recommendations for patients with altered immunocompetence associated with complement deficiencies. Administer required vaccines at least 2 weeks prior to receiving the first dose to patients without a known history of vaccination. If immediate therapy is indicated, consider administering the required vaccine as soon as possible and provide patients with 2 weeks of antibacterial drug prophylaxis.